Literature DB >> 1959368

A comparison of the frequency of stress ulceration and secondary pneumonia in sucralfate- or ranitidine-treated intensive care unit patients.

J M Eddleston1, A Vohra, P Scott, J A Tooth, R C Pearson, R F McCloy, A K Morton, B H Doran.   

Abstract

OBJECTIVE: To compare the frequency of acute stress ulceration and secondary pneumonia caused by aerobic Gram-negative bacilli in ICU patients treated with either sucralfate or ranitidine.
DESIGN: Prospective, randomized study.
SETTING: ICU, university hospital. PATIENTS: Sixty adult patients who were mechanically ventilated and at risk of developing stress ulceration. INTERVENTION: The patients were randomized to receive either sucralfate (1 g every 6 hrs) via the nasogastric tube or iv ranitidine (50 mg every 6 hrs). If the gastric pH was less than 3.5 in the latter group, 30 mL of 0.3M sodium citrate was given via the nasogastric tube.
MEASUREMENTS AND MAIN RESULTS: On admission, the frequency rate of erosion/ulceration (assessed with the endoscope) was 13.5%. After 4 days, this rate had increased to 18% in sucralfate-treated patients and 36% in ranitidine-treated patients (NS). Mean gastric pH was more alkaline in the ranitidine-treated patients (5.50) compared with the sucralfate-treated patients (4.26) (p less than .01). This pH permitted a higher occurrence rate of gastric colonization by aerobic Gram-negative bacilli in ranitidine-treated patients (64.3%) compared with sucralfate-treated patients (23.8%) (p less than .01). Retrograde bacterial colonization from the stomach to oropharynx and trachea occurred more frequently in ranitidine-treated patients compared with sucralfate-treated patients. Ultimately, the occurrence rate of pneumonia was greater in the ranitidine-treated (35.7%) than in the sucralfate-treated patients (10.3%) (p less than .05).
CONCLUSION: Based on our findings, we recommend the adoption of sucralfate for routine prophylaxis against stress ulceration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1959368     DOI: 10.1097/00003246-199112000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  20 in total

Review 1.  Mechanisms of organ dysfunction in critical illness: report from a Round Table Conference held in Brussels.

Authors:  M P Fink; T W Evans
Journal:  Intensive Care Med       Date:  2002-02-08       Impact factor: 17.440

2.  Regulatory effect of histamine on the barrier function of intestinal mucosal.

Authors:  Ligeng Duan; Xiaoli Chen; J W Alexander
Journal:  J Gastrointest Surg       Date:  2010-04-30       Impact factor: 3.452

Review 3.  Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials.

Authors:  Nabil Sultan; Jose Nazareno; James Gregor
Journal:  Can J Gastroenterol       Date:  2008-09       Impact factor: 3.522

Review 4.  Histamine H2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use.

Authors:  J Nash; L Lambert; M Deakin
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 5.  Assessment of gastric acidity in intensive care patients: intermittent pH registration cannot replace continuous pH monitoring.

Authors:  M J Bonten; C A Gaillard; R W Stockbrügger; F H van Tiel; S van der Geest; E E Stobberingh
Journal:  Intensive Care Med       Date:  1996-03       Impact factor: 17.440

6.  Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care.

Authors:  S Pitimana-aree; D Forrest; G Brown; A Anis; X H Wang; P Dodek
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

7.  Pharmacoeconomic analysis of stress ulcer prophylaxis for critically ill patients.

Authors:  G T Schumock; N P Lam; S R Winkler; S X Kong
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

8.  Stress-related Mucosal Disease.

Authors:  Mitchell J. Spirt
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

Review 9.  Gastrointestinal prophylaxis in neurocritical care.

Authors:  Clemens M Schirmer; Joshua Kornbluth; Carl B Heilman; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

10.  In vitro antibacterial activity of sucralfate.

Authors:  D Bergmans; M Bonten; C Gaillard; F van Tiel; S van der Geest; E Stobberingh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.